Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 15 2023 - 12:53PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2023
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Vesting of 2020 Performance Share Plan Top-Up Award
This notification sets out the vesting details of a "top-up"
conditional share award made to the Chief Executive Officer (CEO)
on 6 May 2020 under the GSK 2017 Performance Share Plan ('PSP'),
following the approval of the 2020 Remuneration Policy at the AGM
that year.
This "top-up" PSP award, equivalent to 25% of the CEO's base
salary, was made to deliver in aggregate for 2020 an award level of
575% of base salary, increasing her award level from 550%. It was
subject to the same business performance conditions as the main
2020 award, with a three-year performance period from 1 January
2020 to 31 December 2022. The main 2020 award vesting was
announced on 14 February
2023. The "top-up" award
has now vested on the same basis ie 52% vesting 48% lapsed,
following the third anniversary of the grant. The vested shares are
subject to a further two-year vesting
period.
This notification that follows is for the "top-up" award made to
the CEO and details the PSP conditional award that vested,
including dividends accrued, on 9 May 2023. The balance of
the award has lapsed.
The closing price of Ordinary Shares of GSK plc on the vesting date
was £14.462.
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms E Walmsley
|
b)
|
Position/status
|
Chief Executive Officer
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on the "top-up" award granted
in 2020 under the Company's 2017 Performance Share
Plan
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
10,729
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
Aggregated
volume Price
|
|
e)
|
Date
of the transaction
|
2023-05-09
|
f)
|
Place
of the transaction
|
N/A
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: May
15, 2023
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024